ArticleTheranostics2018
Genes involved in prostate cancer progression determine MRI visibility.
Article in Theranostics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 1 synthesis or guideline pooled it, 78 citations in OpenAlex.
- Refining biopsy strategies stratified by PI-RADS score in men: a systematic review and network meta-analysis.Nature communications · 2026Pooled it
- The utility of PSA density for selection of targeted versus systematic transperineal prostate biopsy: A retrospective cohort study.BJUI compass · 2026Article
- New kids on the block: MRI guided transrectal focused US, TULSA, focal laser ablation, histotripsy - a comprehensive review.Prostate cancer and prostatic diseases · 2026Review
- Prognostic value of MR visibility/invisibility in men on Active Surveillance.Prostate cancer and prostatic diseases · 2025Article
- Redefining Prostate Cancer Precision: Radiogenomics, Theragnostics, and AI-Driven Biomarkers.Cancers · 2025Review
- Transgluteal MRI-targeted biopsy versus transrectal systemic biopsy in prostate cancer diagnosis.International urology and nephrology · 2025Article
- Imaging in focal therapy: advanced ultrasound imaging and mpMRI-a comprehensive review.Prostate cancer and prostatic diseases · 2025Review
- Nano-delivery of miRNA inhibiting CENPF combined with cisplatin for bladder cancer treatment.RSC advances · 2025Article
- Should systematic prostatic biopsies be discontinued?Prostate cancer and prostatic diseases · 2025Review
- Combining tissue biomarkers with mpMRI to diagnose clinically significant prostate cancer. Analysis of 21 biomarkers in the PICTURE study.Prostate cancer and prostatic diseases · 2025Article
- Histopathologic Features and Transcriptomic Signatures Do Not Solve the Issue of Magnetic Resonance Imaging-Invisible Prostate Cancers: A Matched-Pair Analysis.The Prostate · 2025Article
- Assessing the Molecular Heterogeneity of Prostate Cancer Biopsy Sampling: Insights from the MAST Trial.European urology focus · 2025Article
- Malignant epithelial cell marker-driven risk signature enables precise stratification in esophageal cancer.Frontiers in immunology · 2025Article
- Is MRI ready to replace biopsy during active surveillance?European radiology · 2024Review
- Role of Systematic Biopsy in the Era of Targeted Biopsy: A Review.Current oncology (Toronto, Ont.) · 2024Review
- Management of Patients With a Negative Multiparametric Prostate MRI Examination:AJR. American journal of roentgenology · 2024Review
- Lifetime Health and Economic Outcomes of Biparametric Magnetic Resonance Imaging as First-Line Screening for Prostate Cancer : A Decision Model Analysis.Annals of internal medicine · 2024Article
- Systematic review and integrated analysis of prognostic gene signatures for prostate cancer patients.Discover oncology · 2023Article
- Integrating biomarkers and multi-parametric MRI to provide enhanced clinical diagnosis for prostate cancer.Frontiers in urology · 2023Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 1 country.
Funding
Abstract
MRI is used to image prostate cancer and target tumors for biopsy or therapeutic ablation. The objective was to understand the biology of tumors not visible on MRI that may go undiagnosed and untreated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.